Full Press Release Details
Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera Growth
revenues are expected to increase by approximately 35% compared to 2024, which is approximately $40 million above the top end of Natera's
business updates will be presented at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
AUSTIN, Texas, January 11, 2026 -
(BUSINESS WIRE) - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today
released preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. The Company expects the following:
was a record year for oncology, organ health and women's health," said Steve Chapman, CEO of Natera. "The fourth quarter
was particularly strong, with excellent growth in volume, revenue and gross margins. We believe we are well positioned to continue building
on this momentum in 2026 and beyond."
results will be included in a presentation at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at
4:30 pm PT, and also posted to the investor relations section of the Natera website at www.investor.natera.com. Natera will also
present additional business updates at the J.P. Morgan conference.
plans to release its complete fourth quarter and full year 2025 financial results during its earnings call in February 2026.
Natera is a global leader
in cell-free DNA and precision medicine, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic
testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead
to longer, healthier lives. Natera's tests are supported by more than 350 peer-reviewed publications that demonstrate excellent
performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement
Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified
and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.
Forward-Looking Statements
This release contains forward-looking statements,
including our preliminary operational and financial results for the fourth quarter and fiscal year ended December 31, 2025. The preliminary
operational and financial results for the fourth quarter and fiscal year ended December 31, 2025 have not been audited by our independent
registered public accounting firm and are based on management's initial review of our operations and results for the completed fiscal
year. These preliminary operational and financial results are subject to revision based upon our year-end closing procedures, final adjustments
and the audit to be conducted by our independent registered public accounting firm. As a result, our actual operational and financial
results may differ materially from these preliminary results. In addition, these preliminary operational and financial results are not
a comprehensive statement of our operational and financial results for the fourth quarter and for fiscal 2025, and should not be viewed
as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles. Any forward-looking
statements contained in this release are based upon Natera's current plans, estimates, and expectations as of the date of this release,
and are not a representation that such plans, estimates, or expectations will be achieved. Subsequent events may cause these expectations
to change, and Natera disclaims any obligation to update the forward-looking statements in the future.
Our forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual results to differ materially, including: our preliminary operational
and financial results for the fourth quarter and for fiscal 2025 are subject to material changes and adjustments as noted above; we face
numerous uncertainties and challenges in achieving our financial projections and goals; we have incurred net losses since our inception
and we anticipate that we will continue to incur net losses for the foreseeable future; our quarterly results may fluctuate from period
to period; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate. Additional risks and uncertainties
that could affect our financial results are discussed in greater detail in the sections titled "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of Operations" in our most recent filings on Forms 10-K and 10-Q and
in other filings that we make with the SEC from time to time. These documents are available at www.investor.natera.com and on the
SEC's website at www.sec.gov.
Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc.,